Organization · Venture Capital
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets. Founded in 2020, it manages approximately $2 billion in assets and focuses on breakthrough biomedical technology and life sciences companies.
Overview
What Catalio Capital Management does
What Catalio Capital Management is
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets. Founded in 2020, it manages approximately $2 billion in assets and focuses on breakthrough biomedical technology and life sciences companies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2020
- Approximate age
- About 6 years
- Structured capabilities
- Funder
- Last reviewed
- May 6, 2026
Official channels
Find Catalio Capital Management elsewhere
Open the official website or a supported primary organization account.
Capability profile
Catalio Capital Management as a funder
Investment thesis
Catalio Capital Management focuses on investing in breakthrough life-sciences companies and building the next generation of category-defining healthcare businesses across private and public markets.
Focus narrative
Catalio Capital invests in innovative healthcare companies at all stages and sizes, spanning various sectors including drugs, devices, diagnostics, and healthcare-related artificial intelligence. The firm employs multiple strategies, including private equity, structured opportunities, public equities, and co-investments, to facilitate the growth of its portfolio companies.
Value beyond capital
Catalio Capital adds value to its portfolio companies through its extensive network of scientist-entrepreneurs, providing technical diligence, company formation support, and flexible capital solutions. The firm's expertise in healthcare investing allows it to assist companies from inception through IPO, ensuring they have the resources and guidance needed to succeed.
Terms and economics
- Typical check
- $10,000,000–$50,000,000
- Sweet spot
- $15,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Growth Equity · Ipo
- Sectors
- Biotech · Healthcare · Diagnostics · Medical Devices
- Regions
- Global · North America · Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 12
- Recorded notable exits
- Haystack Oncology
Portfolio context
Notable portfolio companies include Affini-T, focused on innovative therapies; Arrivent, expected to IPO in 2024; Atai Life Sciences, which went public in 2021; Audicus, with a loan repayment scheduled for 2025; Bayesian Health, engaged in healthcare AI; Beacon Biosignals, specializing in diagnostics; Cage Pharmaceuticals, focused on drug development; Freenome, involved in diagnostics and AI; Haystack Oncology, which exited in 2023; Iambic, partnered with Takeda for AI drug discovery; Recursion, which went public in 2021; and Visby Medical, focused on diagnostics.
Common questions
What to know about Catalio Capital Management
Upseed classifies Catalio Capital Management under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 6, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.